Background
==========

Helicobacter pylori (H.P.) infection is a major cause of chronic gastritis and peptic ulcers and it is a risk factor for gastric malignancies, adenocarcinoma and low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma \[[@B1]\]. According to the Maastricht III consensus report, H.P. eradication is recommended for patients with gastroduodenal ulcer disease, atrophic gastritis, MALT lymphoma, first degree relatives of patients with gastric cancer, patients with unexplained iron deficiency anemia and chronic idiopathic thrombocytopenic purpura.

In both developed and developing countries, H.P. infection is most frequently acquired during childhood, and it is associated with family size, familial clustering, low socioeconomic status and education. The first line treatment for H.P. infection, as recommended by the Maastricht 2--2000 Consensus Report , is a 7--14 days triple therapy which includes amoxicilline, clarithromycin, OR metronidazole and a proton-pump inhibitor (PPI) \[[@B2]\], though new strategies may be required for treatment both in adults and children. As for adults, "infanti" treatment will fail in approximately 10-35% of patients, and H.P. infection will remain resulting from several factors, including nonadherence to therapy related to adverse effects or complicated dosing regimens and increasing antibiotic resistance \[[@B3]-[@B5]\]. To overcome this problem, both in adults than in children, alternative and adjuvant therapies have been added to conventional treatment, such as probiotics (PB) \[[@B6],[@B7]\]. Although there is some controversy as to whether supplementation with probiotic improves the H.P. eradication rates \[[@B8]-[@B10]\], several meta-analysis and reviews have suggested that probiotics can improve the H.P. eradication rate by approximately 5-10% \[[@B10]-[@B13]\]. However, it is evident that not all probiotics are created equal, that the beneficial effects are strain specific, and each strain must be evaluated individually. Besides treatment studies on children are limited by the small number of infected children in each individual center \[[@B14]-[@B16]\], therefore this study aimed to evaluate whether the addition of a commercially multi-strain probiotics to a 7 days triple therapy in children could improve H.P. eradication rates and reduce the side effects of treatment.

Methods
=======

Between July 2008 and July 2011 children referred to the Department of Pediatrics of the University of Naples with dyspeptic complaints such as heartburn, dyspepsia, nausea and epigastric pain, were enrolled in this study. The study was approved by Ethical Committee of the University of Naples.

Pediatric patients with a clinical, laboratory and endoscopic diagnosis of H.P. positive gastritis and the other conditions necessary H.P. eradication for Maastricht III consensus report were included in the study. Exclusion criteria were: 1) allergy to any of drugs used in the study 2) previous attempts to eradicate H.P. 3) receipt of antibiotics, PPIs or probiotics within 4 weeks of the study. Informed consent was obtained from all patients and all positive 13 C-urea breath test (C13-ubt) patients underwent upper endoscopy.

Two samples were taken from the gastric antrum and compass for histologic assessment, and the biopsy specimens were fixed in 10% formalin solution. Preparation were stained with hematoxylin-eosin and modified Giemsa stains and were evaluated according to updated Sydney classification.

H.P. positive patients were randomized into two therapy regimens: patients in group A were given omeprazole (1 mg/kg before breakfast), amoxicillin (50 mg/kg b.i.d. after meals), clarithromycin (15 mg/kg b.i.d. after meals) for 7 days, whereas patients in group B were given the same drugs and a probiotic once a day for 7 days.

Patients were instructed to take PPI 30 mins before breakfast, the antibiotics 5 mins after breakfast and dinner, and PB supplement in the afternoon. The PB supplement was taken in a commercially available form containing 5 × 109 Lactobacillus plantarum, 2 × 109 L. reuterii, 2 × 109 L. casei subsp. rhamnosus, 2 × 109 Bifidobacterium infantis and B. longum, 1 × 109 L. salivarius, 1 × 109 L. acidophilus, 5 × 109 Streptococcus termophilus, and 1 × 109 L. sporogenes (Lactobacillaceae). This PB formula (5g/dayose q.d.) (Probinul - Cadigroup) was selected because it contains high concentrations of a wide range of bacteria, as well as inuline as a prebiotic.

Parents were asked to report any side effects of therapy during the treatment period and were given a possible side effect list, such as epigastric pain, nausea, diarrhea and constipation. Patients compliance was evaluated at the end of the treatment on the basis of diary that patients were asked to fill with pill count and was considered as completed if \>90% of the medication had been taken.

Successful eradication was defined as a negative C13-ubt result four weeks after discontinuation of the therapy.

Statistical analysis
--------------------

Data were collected prospectically in an electronic database (Excell Microsoft). Fisher's exact test was carried out to determine the efficacy of the two treatments. Results were considered statistically significant for P values less than 0.05.

Results
=======

A total of 68 histopathologically proven H.P.-infection children (32 male and 36 females) were included in the study. The mean age of all children was 8,3 +/− 3,4 years.

The patients were randomized into group A (triple therapy n 34 patients) and group B (triple therapy plus probiotic n 34 patients) for H.P. eradication. The age distribution of patients and gender in group A and group B were similar.

All of parents returned the daily diary filled up with side-effects and pill count.

All of the patients in both groups used more than 90% of the therapies and no patients were lost at follow up. The prevalence of epigastric pain, nausea, vomiting and diarrhea was significantly higher (P\<0.05) in group A than in group B . There was no significant difference between the two groups in terms of constipation. (Detailed data on side effects are summarized in Table [1](#T1){ref-type="table"}).

###### 

Incidence of side effects of the treatment

  **Side Effects**     **Group A** (**N**=**34**)   **Group B** (**N**=**34**)   **P value**
  ------------------- ---------------------------- ---------------------------- -------------
  *Epigastric pain*            6 (17.6%)                     2 (5.8%)              \<0.05
  *Nausea*                      3 (8.8%)                     1 (2.9%)              \<0.05
  *Vomiting*                    2 (5.8%)                        0                  \<0.05
  *Diarrhea*                   8 (23.5%)                        0                  \<0.05
  *Constipation*                2 (5.8%)                     2 (5.8%)               N.S.

All side effects were self-limiting and disappeared once the therapy was terminated.

Four weeks after the completion of therapy, 56/68 patients (82.3%) tested negative for H.P. on C13-ubt. H.P. was eradicated in 26 patients (76.4%) in group A and in 30 patients (88.2%) in group B (Figure [1](#F1){ref-type="fig"}). There was no significantly difference in the rate of H.P. eradication between group A and group B (p=0,1), although the success rate for H.P. eradication was higher in group B than in group A.

![Patients enrollment and therapy flowchart.](1824-7288-38-63-1){#F1}

Discussion
==========

It is well known that childhood is an important period for acquisition of H.P. infection. Intrafamiliar trasmission of the infection , especially from mother to child, has been hypothisized as the major mode of dissemination \[[@B17]\]. H.P. is considered to be the major cause of chronic gastritis and duodenal ulcer in childhood and an important cofactor in the development of gastric cancer \[[@B18]\]. Unfortunately eradication therapy is not always successful and reports of failed H.P. eradication therapy are increasing. Therefore, recent review studies report eradication rates of standard triple therapy in children below 75% \[[@B14],[@B19]\]. Moreover this regimens have the disadvantage of risking poor compliance and causing side-effects especially in children. Nowadays there is considerable interest in alternative therapies or adjunctive treatment against H.P. to reduce some of the drawbacks associated with the antibiotic consumption and to increase the eradication rates. Some adjuvant therapy trials both in adults and in children incorporate probiotics \[[@B20]-[@B22]\].

In our study H.P. eradication was achieved in 82.3% of patients. A little increase in the eradication rate and a significant reduction in side effects were observed in the group treated with triple therapy plus Probinul PB. Resistant patients were offered to second line therapy (omeprazole 1 mg/kg/d, amoxicillin 50 mg/kg/d and metronidazole 20 mg/kg/d), according to NASPGHAN guidelines, confirming the contribution of a high background resistance to clarithromycin. Also, guidelines on HP infection in children issued so far suggest that the antibiotic susceptibility test should be performed whenever available \[[@B15]\]. However, we did not performed susceptibility test for first line antibiotic therapy.

Probiotics include viable microorganism that have a beneficial effects for the prevention and treatment of specific pathological conditions \[[@B23]\]. Principle mechanisms include interference with pathogenic toxins, preservation of cellular physiology , interference with pathogen attachment and interaction with normal microbiota \[[@B24],[@B25]\] .

In addition, stimulation or modulation of immune responses, both within the lumen and systemically, although not clearly linked to H.P. infection, may contribute \[[@B26],[@B27]\]. Besides probiotics may be beneficial in reducing adverse effects and increasing tolerability of HP eradication regimens. Several studies evaluated whether probiotic supplementation might help to prevent or reduce drug-related side effects during H.P. eradication therapy in adults \[[@B28]-[@B30]\]. Up to date, in the pediatric population, few randomized studies have evaluated whether consumption of probiotics could increase H.P. eradication rates and reduce the side effects of treatment \[[@B31]-[@B33]\]. In fact, in a recent trial by Szajewska et al. \[[@B33]\] was identified that the use of Lactobacillus GG along with standard triple therapy didn't resulted in an increased eradication rate and decreased overall therapy-related side effects.

Some of these trials do not provide evidence on the beneficial effect in children of supplementation of probiotics to triple therapy for eradicating H.P. infection nor for positively affecting therapy related symptoms and overall treatment tolerance \[[@B34]\].

However other investigators have shown that in symptomatic H.P. positive children, the occurrence of antibiotic associated side-effects was significantly reduced by the addition of probiotics compared with the placebo supplemented group \[[@B31]\].

H.P. eradication depends on a number of factor, including patients compliance, adverse effects, bacterial resistance, poor drug distribution and concentration, socio-economic conditions and geographic differences. So antibiotic related side effects may be depending on different probiotic strains taken during the H.P. eradication therapy.

In our study the choice of the Probinul probiotic formula was determinated by the fact that it contains high concentration of a wide range of bacteria, as well as inuline as prebiotic. Previously we have demonstrated that this probiotic formula was able to reduce antibiotic gastro-intestinal related side effects in children treated with amoxicillin therapy for pneumonia infections \[[@B35]\].

Besides De Bortoli et al. have demonstrated that the addition of bovine lactoferrin and this probiotic formula to standard triple eradication therapy could improve the H.P. eradication rate and reduce side effects in adult \[[@B36]\].

In this study the combination of standard triple therapy + probiotic + bovine lactoferrin was more effective than triple therapy alone. This could be explained by the combined effect of the bactericidal and bacteriostatic properties of bovine lactoferrin and the mechanism of the probiotics including their direct, nonspecific, bacteriostatic activity and their enhancement of immunoglobulin A production \[[@B37]\].

Probiotics may act through both immunological as well as non-immunological mechanism in H.P. eradication. The latest mechanism includes providing antimicrobial substances, competing with H.P. for adhesion and providing a mucosal barrier. When there are decreases in side effects, compliance improves \[[@B26]\]. The efficacy of probiotic supplementation for reducing side effects during the course of anti HP regimens appears to be dependent of which probiotic species are used. In fact probiotics must be metabolically active in the intestinal lumen, where they should survive but not persist after the therapy regimen has been completed. They must be acid and bile resistant and should be antagonist to pathogenic bacteria \[[@B38]-[@B40]\].

The present study has shown that the addiction of the Probinul probiotic formula to standard antibiotic treatment reduced in children H.P. therapy-associated side effects (occurrence of side effects: 61.5% in group A vs 14.5% in group B). The H.P. eradication was achieved in 26 of 34 patients in group A (76.4%) and in 30 of 34 patients (88.2%) in group B. Although the success rate was higher in group A than in group B, the different was not significant. Also, we preferred to use the conventional 7-days triple therapy to better highlight the efficacy of probiotic supplement; furthermore extending the duration of therapy form 7 to 14 days is not clearly associated with an increased eradication rate \[[@B41]\]. However, our study presents some limitations, as a relative small number of patients and absence of a placebo-control group for the probiotics; also, the treatment group with probiotics is likely to be superior to the control group if the sample size is larger.

In conclusion our study suggests that the addition of this probiotic formula to triple therapy did not increase (significantly) the H.P. eradication rates; however it significantly decreased the frequency of epigastric pain, nausea, vomiting and diarrhea.

In children with H.P. infection, we think, there is evidence to recommend the use of this probiotic formula along with standard triple therapy as an option for decreasing overall therapy related side effects and slightly increasing the eradication rates.
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